Analyst Ratings For Axovant Sciences (NASDAQ:AXON)
Today, JPMorgan Chase & Co. raised its price target on Axovant Sciences (NASDAQ:AXON) to per share.
Some recent analyst ratings include
- 2/13/2018-Cowen Reiterated Rating of Hold.
- 2/13/2018-Oppenheimer Reiterated Rating of Hold.
- 1/10/2018-Chardan Capital Upgrade from a “Sell ” rating to a ” Neutral” rating.
- 12/21/2017-Jefferies Group was Downgraded by analysts at Jefferies Group from a “Buy ” rating to a ” Hold” rating. They now have a $6.00 price target on the stock.
- 12/1/2017-HC Wainwright Reiterated Rating of Buy.
- 11/10/2017-Piper Jaffray Companies Reiterated Rating of Hold.
Recent Insider Trading Activity For Axovant Sciences (NASDAQ:AXON)
Axovant Sciences (NASDAQ:AXON) has insider ownership of 72.40% and institutional ownership of 93.52%.
- On 4/17/2017 David Hung, Insider, bought 539,375 with an average share price of $18.54 per share and the total transaction amounting to $10,000,012.50.
- On 4/17/2017 W Anthony Vernon, Director, bought 53,937 with an average share price of $18.54 per share and the total transaction amounting to $999,991.98.
- On 3/10/2016 Mark Altmeyer, Insider, bought 2,300 with an average share price of $11.14 per share and the total transaction amounting to $25,622.00.
Recent Trading Activity for Axovant Sciences (NASDAQ:AXON)
Shares of Axovant Sciences closed the previous trading session at 1.49 up +0.03 2.05% with shares trading hands.
